Folyóiratcikkek tallózása szerző szerint "Moreau P"

1-5 / 5

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.

Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi, Tamás; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A; the ASPIRE Investigators (2014)

Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase ...
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos MA; Stewart AK; Masszi, Tamás; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A (2017)

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomi ...
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Mateos MV; Masszi, Tamás; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P (2017)

Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study ...
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi, Tamás; Spencer A; Hajek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG (2017)

The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma ...
Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Leleu X; Masszi, Tamás; Bahlis NJ; Viterbo L; Baker B; Gimsing P; Maisnar V; Samoilova O; Rosinol L; Langer C; Song K; Izumi T; Cleeland C; Berg D; Lin HM; Zhu YY; Skacel T; Moreau P; Richardson PG (2018)

TOURMALINE-MM1 is a phase III, randomized, double-blind, placebo-controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma following 1-3 ...

1-5 / 5

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban
Ebben a gyűjteményben

Hozzáférésem

Bejelentkezés

Folyóiratcikkek tallózása szerző szerint "Moreau P"

DSpace/Manakin Repository

Folyóiratcikkek tallózása szerző szerint "Moreau P"

Keresés

Tallózás

Teljes repozitórumban

Ebben a gyűjteményben

Hozzáférésem